New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 30, 2017 – Teva announced the FDA approval of Austedo (deutetrabenazine) for the treatment of tardive dyskinesia (TD) in adults.
Download PDF
Return to publications
